sur IFabric Corp (CVE:IFA)
IFabric's Clinical Trial Validates Infection Control with Treated Scrubs
IFabric Corp announced that the Journal of Hospital Infection has published the results of a clinical trial demonstrating the effectiveness of their antimicrobial-treated fabric scrubs. Conducted by Intelligent Fabric Technologies at Saddleback Medical Center, this study showcased significant reductions in bacterial loads on scrubs treated with PROTX2® and ecoPEL™ technology.
The trial emphasized the superiority of these treated scrubs over untreated ones, suggesting a substantial impact on infection control in healthcare settings. Giancarlo Beevis, CEO of IFTNA, highlighted the potential of PROTX2® as a pivotal solution in reducing healthcare-associated infections, asserting its unmatched industry performance.
The technology is registered with the EPA and available in the United States, promising economic benefits for healthcare facilities by lowering infection rates and associated costs.
R. E.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de IFabric Corp